Vitiligo, depigmented macules resulting from the loss of melanocytes, occurred mostly in melanoma patients treated with ICIs, while it also occurred in lung cancer patients.5 The PD‐L1/PD‐1 pathway probably mediates peripheral tolerance of melanosomal proteins, and PD‐1 inhibitor may induce vitiligo.6 Grover's disease, which presents as an intensely pruritic, papulovesicular rash, is a rare dermatologic toxicity. This evidence concerns the gene PDCD1 and vitiligo.